Clinical Trials Browser

Active not recruiting × Melanoma × Interferon alpha-2 × Clear all

NCT02506153 2026-03-18

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,301 enrolled 16 charts

Melanoma

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Phase 3 Active not recruiting

1,150 enrolled 6 charts

Melanoma

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,673 enrolled 19 charts

Melanoma

NCT01708941 2025-11-26

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Active not recruiting

88 enrolled 14 charts

Melanoma